Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study.
Merkel D, Filanovsky K, Gafter-Gvili A, Vidal L, Aviv A, Gatt ME, Silbershatz I, Herishanu Y, Arad A, Tadmor T, Dally N, Nemets A, Rouvio O, Ronson A, Herzog-Tzarfati K, Akria L, Braester A, Hellmann I, Yeganeh S, Nagler A, Leiba R, Mittelman M, Ofran Y. Merkel D, et al. Among authors: arad a. Am J Hematol. 2013 Feb;88(2):130-4. doi: 10.1002/ajh.23368. Am J Hematol. 2013. PMID: 23345248 Free article.
Higher infection rate after 7- compared with 5-day cycle of azacitidine in patients with higher-risk myelodysplastic syndrome.
Ofran Y, Filanovsky K, Gafter-Gvili A, Vidal L, Aviv A, Gatt ME, Silbershatz I, Herishanu Y, Arad A, Tadmor T, Dally N, Nemets A, Rouvio O, Ronson A, Herzog-Tzarfati K, Akria L, Braester A, Hellmann I, Yeganeh S, Nagler A, Leiba R, Mittelman M, Merkel D. Ofran Y, et al. Among authors: arad a. Clin Lymphoma Myeloma Leuk. 2015 Jun;15(6):e95-9. doi: 10.1016/j.clml.2015.02.030. Epub 2015 Mar 5. Clin Lymphoma Myeloma Leuk. 2015. PMID: 25819366
Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the "3 + 7" induction regimen for acute myeloid leukemia.
Ofran Y, Leiba R, Ganzel C, Saban R, Gatt M, Ram R, Arad A, Bulvik S, Hellmann I, Gino-Moor S, Zuckerman T, Hoffman R, Horowitz N, Lavi N, Ringelstein S, Henig I, Hayun M, Rowe JM. Ofran Y, et al. Among authors: arad a. Am J Hematol. 2015 Dec;90(12):1159-64. doi: 10.1002/ajh.24207. Epub 2015 Nov 17. Am J Hematol. 2015. PMID: 26435038 Free article.
Richter's transformation to diffuse large B-cell lymphoma: a retrospective study reporting clinical data, outcome, and the benefit of adding rituximab to chemotherapy, from the Israeli CLL Study Group.
Tadmor T, Shvidel L, Bairey O, Goldschmidt N, Ruchlemer R, Fineman R, Rahimi-Levene N, Herishanu Y, Yuklea M, Arad A, Aviv A, Polliack A; Israeli CLL Study Group. Tadmor T, et al. Among authors: arad a. Am J Hematol. 2014 Nov;89(11):E218-22. doi: 10.1002/ajh.23826. Epub 2014 Sep 2. Am J Hematol. 2014. PMID: 25110869 Free article.
Bone marrow blast elimination by the fifth day of 7 + 3 induction is the strongest predictor of potential cure in patients with acute myeloid leukemia younger than 61 years of age: A long-term follow-up of a multi-center prospective study.
Ofran Y, Hayun M, Leiba R, Zuckerman T, Horowitz N, Hoffman R, Ringelstein S, Lavi N, Frisch A, Henig I, Gatt ME, Hellmann I, Arad A, Bulvik S, Ram R, Gino-Moor S, Saban R, Tvito A, Rowe JM, Ganzel C. Ofran Y, et al. Among authors: arad a. Am J Hematol. 2020 Jan;95(1):E3-E5. doi: 10.1002/ajh.25651. Epub 2019 Oct 17. Am J Hematol. 2020. PMID: 31591736 Free article. No abstract available.
Outcomes of second-line treatment after fludarabine cyclophosphamide and rituximab in patients with chronic lymphocytic leukemia outside clinical trials.
Joffe E, Goldschmidt N, Bairey O, Fineman R, Ruchlemer R, Rahimi-Levene N, Shvidel L, Greenbaum U, Aviv A, Tadmor T, Braester A, Arad A, Polliack A, Herishanu Y; Israeli CLL Study Group. Joffe E, et al. Among authors: arad a. Eur J Haematol. 2018 Sep;101(3):399-406. doi: 10.1111/ejh.13129. Epub 2018 Aug 3. Eur J Haematol. 2018. PMID: 29949186
A new risk model to predict time to first treatment in chronic lymphocytic leukemia based on heavy chain immunoparesis and summated free light chain.
Tadmor T, Braester A, Najib D, Aviv A, Herishanu Y, Yuklea M, Shvidel L, Rahimi-Levene N, Ruchlemer R, Arad A, Fogl C, Henig C, Barak M, Magal L, Polliack A, Townsend K; Israeli CLL study group. Tadmor T, et al. Among authors: arad a. Eur J Haematol. 2019 Oct;103(4):335-341. doi: 10.1111/ejh.13288. Epub 2019 Jul 26. Eur J Haematol. 2019. PMID: 31278876
64 results